{"disease":{"id":"congenital-cytomegalovirus-infection","name":"Congenital cytomegalovirus infection","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":1,"trial_count":1},"drugs":{"marketed":[{"drug_id":"valganciclovir","indication_name":"Congenital cytomegalovirus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Valcyte","generic_name":"VALGANCICLOVIR","company_name":"Cheplapharm","drug_phase":"marketed","molecular_target":"","drug_class":"Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor","quality_score":70,"revenue":null,"mechanism":"Valcyte works by inhibiting the replication of cytomegalovirus DNA through its action as a nucleoside analog DNA polymerase inhibitor."}],"pipeline":[{"drug_id":"valacyclovir","indication_name":"Congenital Cytomegalovirus Infection","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"VALACYCLOVIR","company_name":"","drug_phase":"marketed","molecular_target":"Viral DNA polymerase","drug_class":"Nucleoside analogue","quality_score":80,"revenue":null,"mechanism":"Valacyclovir is an antiviral drug that inhibits viral DNA polymerase to treat herpes simplex and varicella-zoster viruses."}],"offLabel":[],"totalMarketed":1,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT05754879","title":"Diagnosis of Congenital Cytomegalovirus Infection in Newborn With Particular Risk","phase":"","overall_status":"COMPLETED","enrollment_count":479,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT01923636","title":"Prognostic Value of Neonatal Markers for the Development of Neurosensorial Sequelae in Children Infected by Cytomegalovirus in Utero","phase":"NA","overall_status":"COMPLETED","enrollment_count":254,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT02139423","title":"Diagnosis of Congenital CMV Infection in Neonates Who Failed Newborn Hearing Screening","phase":"NA","overall_status":"COMPLETED","enrollment_count":235,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05170269","title":"Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14 (PreCyssion)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":48,"lead_sponsor_name":"Biotest","has_results":false},{"nct_id":"NCT02005822","title":"Congenital Cytomegalovirus: Efficacy of Antiviral Treatment","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Dr. Ann C.T.M. Vossen","has_results":false},{"nct_id":"NCT06118515","title":"A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT03301415","title":"Asymptomatic Congenital CMV Treatment","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}